Diabetes and Antiplatelet Therapy in Acute Coronary Syndrome

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Circulation

• Publication date

  2011-02-22

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/CIRCULATIONAHA.109.913376PMID 21343595
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II.

  2013cited by this paper
• A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial

  2011cited by this paper
• Diagnosis and Classification of Diabetes Mellitus

  2011cited by this paper
• Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes（JPAD）Trial

  2011cited by this paper
• Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes

  2011cited by this paper
• Functional profile of the platelet P2Y12 receptor signalling pathway in patients with type 2 diabetes mellitus and coronary artery disease

  2011cited by this paper
• Diagnosis and Classification of Diabetes Mellitus

  2010cited by this paper
• Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial

  2010cited by this paper
• New oral anticoagulants: a practical guide for clinicians

  2010cited by this paper
• Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy.

  2010cited by this paper
• Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.

  2010cited by this paper
• Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.

  2010cited by this paper
• Role of platelets in atherothrombosis.

  2009cited by this paper
• Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study.

  2009cited by this paper
• Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials

  2009cited by this paper
• Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials

  2009cited by this paper
• Reconstituted High-Density Lipoprotein Attenuates Platelet Function in Individuals With Type 2 Diabetes Mellitus by Promoting Cholesterol Efflux

  2009cited by this paper
• Insulin/IGF‐1 hybrid receptor expression on human platelets: consequences for the effect of insulin on platelet function

  2009cited by this paper
• Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial).

  2009cited by this paper
• Clopidogrel response variability: Current status and future directions

  2009cited by this paper
• Platelet dysfunction in central obesity.

  2009cited by this paper
• Intravenous platelet blockade with cangrelor during PCI.

  2009cited by this paper
• Variability in responsiveness to oral antiplatelet therapy.

  2009cited by this paper
• Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials

  2009cited by this paper
• Effects of Intensive Glucose Lowering in Type 2 Diabetes

  2009cited by this paper
• Antiplatelet Therapy in Diabetes: Efficacy and Limitations of Current Treatment Strategies and Future Directions

  2009cited by this paper
• Predictors and impact of bleeding complications in percutaneous coronary intervention, acute coronary syndromes, and ST-segment elevation myocardial infarction.

  2009cited by this paper
• Platelet inhibition with cangrelor in patients undergoing PCI.

  2009cited by this paper
• Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.

  2009cited by this paper
• TP Receptor Antagonism: A New Concept in Atherothrombosis and Stroke Prevention

  2009cited by this paper
• Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study.

  2009cited by this paper
• Association Between Increased Platelet P-Selectin Expression and Obesity in Patients With Type 2 Diabetes

  2009cited by this paper
• Low-Dose Aspirin for Primary Prevention of Atherosclerotic Events in Patients With Type 2 Diabetes: A Randomized Controlled Trial

  2009cited by this paper
• Insulin, Insulin Resistance, and Platelet Signaling in Diabetes

  2009cited by this paper
• Platelet thrombin receptor antagonism and atherothrombosis

  2009cited by this paper
• Impact of P2Y(12) inhibitory effects induced by clopidogrel on platelet procoagulant activity in type 2 diabetes mellitus patients.

  2009cited by this paper
• Factors Contributing to Increased Platelet Reactivity in People With Diabetes

  2009cited by this paper
• Dabigatran versus warfarin in patients with atrial fibrillation.

  2009cited by this paper
• Ticagrelor versus clopidogrel in patients with acute coronary syndromes.

  2009cited by this paper
• Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease

  2008cited by this paper
• Platelet activation and atherothrombosis.

  2008cited by this paper
• Writing Committee Members

  2008cited by this paper
• Letter by Klein Regarding Article, "Evaluation of Dose-Related Effects of Aspirin on Platelet Function: Results From the Aspirin-Induced Platelet Effect (ASPECT) Study"

  2008cited by this paper
• Clinical overview of promising nonthienopyridine antiplatelet agents.

  2008cited by this paper
• Determinants of mean platelet volume (MPV) in an elderly population: Relevance of body fat, blood glucose and ischaemic electrocardiographic changes

  2008cited by this paper
• 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines.

  2008cited by this paper
• Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.

  2008cited by this paper
• Safety and efficacy of bivalirudin monotherapy in patients with diabetes mellitus and acute coronary syndromes: a report from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.

  2008cited by this paper
• Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial.

  2008cited by this paper
• Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention.

  2008cited by this paper
• Letter by Klein regarding article, "Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study".

  2008cited by this paper
• Platelet Sarcoplasmic Endoplasmic Reticulum Ca2+-ATPase and &mgr;-Calpain Activity Are Altered in Type 2 Diabetes Mellitus and Restored by Rosiglitazone

  2008cited by this paper
• Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients).

  2008cited by this paper
• Endothelial dysfunction, impaired endogenous platelet inhibition and platelet activation in diabetes and atherosclerosis.

  2008cited by this paper
• 2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention

  2008cited by this paper
• Comment on: DiChiara et al. (2007) The Effect of Aspirin Dosing on Platelet Function in Diabetic and Nondiabetic Patients: An Analysis From the Aspirin-Induced Platelet Effect (ASPECT) Study: Diabetes 56:3014–3019, 2007

  2008cited by this paper
• Infliximab treatment shifts the balance between stimulatory and inhibitory Fcgamma receptor type II isoforms on neutrophils in patients with rheumatoid arthritis.

  2008cited by this paper
• Pharmacology of emerging novel platelet inhibitors.

  2008cited by this paper
• Effects of intensive glucose lowering in type 2 diabetes.

  2008cited by this paper
• Oxidative stress and platelets.

  2008cited by this paper
• Platelet-vessel wall interactions in atherosclerotic disease

  2008cited by this paper
• Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.

  2008cited by this paper
• A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study.

  2008cited by this paper
• Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis

  2008cited by this paper
• Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease.

  2008cited by this paper
• Prevention by NCX 4016, a nitric oxide-donating aspirin, but not by aspirin, of the acute endothelial dysfunction induced by exercise in patients with intermittent claudication

  2007cited by this paper
• Randomized Comparison of a High Clopidogrel Maintenance Dose in Patients With Diabetes Mellitus and Coronary Artery Disease: Results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) Study

  2007cited by this paper
• Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes.

  2007cited by this paper
• Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of clopidogrel before percutaneous coronary intervention.

  2007cited by this paper
• Platelet activation and atherothrombosis.

  2007cited by this paper
• Impact of weight reduction on production of platelet-derived microparticles and fibrinolytic parameters in obesity.

  2007cited by this paper
• Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.

  2007cited by this paper
• Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives.

  2007cited by this paper
• The Effect of Aspirin Dosing on Platelet Function in Diabetic and Nondiabetic Patients

  2007cited by this paper
• Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.

  2007cited by this paper
• Reticulated platelets and uninhibited COX‐1 and COX‐2 decrease the antiplatelet effects of aspirin

  2007cited by this paper
• Platelet aggregation in obese and diabetic subjects: Association with leptin level

  2007cited by this paper
• Insulin-like growth factor-1 potentiates platelet activation via the IRS/PI3Kα pathway

  2007cited by this paper
• Insulin-like growth factor-1 potentiates platelet activation via the IRS/PI3Kalpha pathway.

  2007cited by this paper
• Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis.

  2007cited by this paper
• Alterations of Adenine Nucleotide Metabolism and Function of Blood Platelets in Patients With Diabetes

  2007cited by this paper
• Prasugrel versus clopidogrel in patients with acute coronary syndromes.

  2007cited by this paper
• Prasugrel Compared With High Loading– and Maintenance–Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention: The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation–Thrombolysis in Myocardial Infarction 44 Trial

  2007cited by this paper
• Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary Syndromes

  2006cited by this paper
• Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial.

  2006cited by this paper
• Effects of VLDL and Remnant Particles on Platelets

  2006cited by this paper
• Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment.

  2006cited by this paper
• Bivalirudin for patients with acute coronary syndromes.

  2006cited by this paper
• Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention.

  2006cited by this paper
• Platelet and monocyte activation by hyperglycemia and hyperinsulinemia in healthy subjects

  2006cited by this paper
• Residual Arachidonic Acid–Induced Platelet Activation via an Adenosine Diphosphate–Dependent but Cyclooxygenase-1– and Cyclooxygenase-2–Independent Pathway: A 700-Patient Study of Aspirin Resistance

  2006cited by this paper
• Effects of improved metabolic control on platelet reactivity in patients with type 2 diabetes mellitus following coronary angioplasty

  2006cited by this paper
• Treatment disparities in the care of patients with and without diabetes presenting with non-ST-segment elevation acute coronary syndromes.

  2006cited by this paper
• Safety of Coronary Sirolimus-Eluting Stents in Daily Clinical Practice: One-Year Follow-Up of the e-Cypher Registry

  2006cited by this paper
• Correlates and Long-Term Outcomes of Angiographically Proven Stent Thrombosis With Sirolimus- and Paclitaxel-Eluting Stents

  2006cited by this paper
• Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.

  2006cited by this paper
• Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.

  2005cited by this paper
• Aspirin resistance: position paper of the Working Group on Aspirin Resistance

  2005cited by this paper
• Atherothrombosis and high-risk plaque: part I: evolving concepts.

  2005cited by this paper
• Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.

  2005cited by this paper

• Combining the P2Y12 antagonist cangrelor with energy metabolism inhibitors has a synergistic antiaggregatory effect.

  2025cites this paper
• Metabolic Dysregulation in Acute Coronary Syndrome: The Link Between Diabetes and Insulin Resistance

  2025cites this paper
• Long-term safety of oral antiplatelet strategies for patients with acute coronary syndrome undergoing percutaneous coronary intervention.

  2025cites this paper
• Comparison of 1-Year Clinical Outcomes Between Ticagrelor Versus Clopidogrel in Type 2 Diabetes Patients After Implantation of Small Diameter Stents

  2025cites this paper
• One- versus three-month DAPT after everolimus-eluting stent implantation in diabetic patients at high bleeding risk: results from the XIENCE Short DAPT programme.

  2025cites this paper
• Association between hemoglobin, albumin, lymphocyte, and platelet score and all-cause and cardiovascular mortality among population with diabetes: Evidence from the NHANES 2003-2016.

  2025cites this paper
• Integrated metabolic-inflammatory risk assessment: HbA1c/HDL-c and hsCRP-to-albumin ratios synergistically predict major adverse cardiovascular events in post-PCI STEMI patients

  2025cites this paper
• Dual antiplatelets therapy prescription trends and mortality outcomes among senior citizens with acute coronary syndrome: insights from the Malaysian National Cardiovascular Disease Database.

  2025cites this paper
• Platelet-Fibrin Clot Strength for Risk Stratification After PCI in Patients With Diabetes Mellitus: Finding the Sweet Spot.

  2025cites this paper
• Diabetic Status and Thrombogenicity: Association and Prognostic Implications After Percutaneous Coronary Intervention.

  2025cites this paper
• Optimizing selection of P2Y12 inhibiting therapy: clopidogrel, prasugrel or ticagrelor

  2025cites this paper
• Catheter ablation in patients with atrial fibrillation and cancer: a systematic review and updated meta-analysis.

  2025cites this paper
• Methoxyflurane Instead of Morphine in Acute Coronary Syndrome Patients: Results of the Randomized Controlled METHANE-SIRIO 4 Study

  2025cites this paper
• Clopidogrel-Mediated P2Y12 Inhibition According to Renal Function in Patients With Diabetes Mellitus and CAD

  2024cites this paper
• Pharmacotherapy for Coronary Artery Disease and Acute Coronary Syndrome in the Aging Population

  2024cites this paper
• Ticagrelor monotherapy after a short course of dual antiplatelet therapy with ticagrelor plus aspirin following percutaneous coronary intervention in patients with versus without diabetes mellitus: a meta-analysis of randomized trials

  2024cites this paper
• Acute Hyperglycemia-Induced Injury in Myocardial Infarction

  2024cites this paper
• Methionine sulfoxide reductase B2 protects against cardiac complications in diabetes mellitus

  2024cites this paper
• Real-time platelet P2Y12 receptor occupancy as a promising pharmacodynamics biomarker for bridging the gap between PK/PD of clopidogrel therapy

  2024cites this paper
• Impact of Diabetes Mellitus on Platelet Reactivity after Percutaneous Coronary Intervention: Data from 3 Different Platelet Function Assays

  2023cites this paper
• Is Coronary Artery Bypass Grafting (CABG) Surgery Still Preferable to Percutaneous Coronary Intervention (PCI) in View of Long-Term Outcomes among Diabetic Patients?

  2023cites this paper
• The Combined Effect of Systemic Immune-Inflammation Index and Type 2 Diabetes Mellitus on the Prognosis of Patients Undergoing Percutaneous Coronary Intervention: A Large-Scale Cohort Study

  2023cites this paper
• The Importance of Prediabetes Screening in the Prevention of Cardiovascular Disease

  2023cites this paper
• Tailoring Antithrombotic Regimens for Percutaneous Coronary Intervention Patients with High Bleeding and Ischemic Risk (TAILOR-BIRISK): Individualized Management and Genotype-Guided De-escalation

  2023cites this paper
• Depression Following Acute Coronary Syndrome: A Review

  2023cites this paper
• Appropriateness of aspirin use among diabetic patients in primary prevention of atherosclerotic cardiovascular diseases: an analysis of the ASSOS study.

  2023cites this paper
• Transcriptome-wide map of N6-methyladenosine (m6A) profiling in coronary artery disease (CAD) with clopidogrel resistance

  2023cites this paper
• Endothelial YAP Mediates Hyperglycemia-Induced Platelet Hyperactivity and Arterial Thrombosis

  2023cites this paper
• Comment on: Managing the acute coronary syndrome patient: Evidence based recommendations for anti-platelet therapy.

  2023cites this paper
• The Cellular and Protein Arms of Coagulation in Diabetes: Established and Potential Targets for the Reduction of Thrombotic Risk

  2023cites this paper
• Prasugrel dose de-escalation in diabetic patients with acute coronary syndrome receiving percutaneous coronary intervention: Results from HOST-REDUCE-POLYTECH-ACS trial.

  2023cites this paper
• Cardiovascular and Bleeding Events of Ticagrelor Monotherapy after Short-term Dual Antiplatelet Therapy (DAPT) in Diabetics and Non-Diabetics Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis

  2023cites this paper
• Short‐term dual antiplatelet therapy in diabetic patients admitted for acute coronary syndrome treated with a new‐generation drug‐eluting stent

  2022cites this paper
• The antioxidant, anti-inflammatory, and antiplatelet effects of Ribes rubrum L. fruit extract in the diabetic rats.

  2022cites this paper
• Endothelial biomarkers and platelet reactivity on ticagrelor versus clopidogrel in patients after acute coronary syndrome with and without concomitant type 2 diabetes: a preliminary observational study

  2022influential citation
• Inverse agonist efficacy of selatogrel blunts constitutive P2Y12 receptor signaling by inducing the inactive receptor conformation.

  2022cites this paper
• Impact of diabetes mellitus on the pharmacodynamic effects of prasugrel and ticagrelor after switching from clopidogrel in patients with coronary artery disease

  2022cites this paper
• The “sweet” relations between diabetes and platelets

  2022cites this paper
• Effects of DPP4 Inhibitor in Platelet Reactivity and Other Cardiac Risk Markers in Patients with Type 2 Diabetes and Acute Myocardial Infarction

  2022cites this paper
• On‐Treatment Platelet Reactivity and Ischemic Outcomes in Patients With Diabetes Mellitus: Two‐Year Results From ADAPT‐DES

  2022cites this paper
• Ischemic-hemorrhagic balance in diabetic and non-diabetic patients after acute coronary syndrome

  2022cites this paper
• Antiplatelet efficacy of ticagrelor versus clopidogrel in Mediterranean patients with diabetes mellitus and chronic coronary syndromes: A crossover pharmacodynamic investigation

  2022cites this paper
• Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD.

  2022cites this paper
• Comparative Efficacy and Safety of P2Y12 Inhibitor Monotherapy and Dual Antiplatelet Therapy in Patients with and without Diabetes Mellitus Undergoing Percutaneous Coronary Intervention

  2022cites this paper
• The Impact of Diabetes Mellitus on Clinical Outcomes after Percutaneous Coronary Intervention with Different Stent Sizes

  2022cites this paper
• Ticagrelor Versus Clopidogrel in East Asian Patients With Acute Coronary Syndrome and Diabetes Mellitus

  2022cites this paper
• Clinical implications of diabetes mellitus in patients with acute coronary syndrome: prognostic role and use of new P2Y12 receptor inhibitors.

  2022cites this paper
• Effect of Platelet Inhibition by Cangrelor Among Obese Patients Undergoing Coronary Stenting: Insights From CHAMPION

  2022cites this paper
• Aspirin for Primary Cardiovascular Prevention in Patients with Diabetes: Uncertainties and Opportunities.

  2022cites this paper
• Selective Autophagy in Hyperglycemia-Induced Microvascular and Macrovascular Diseases

  2021cites this paper
• Impact of Comorbidities and Antiplatelet Regimen on Platelet Reactivity Levels in Patients Undergoing Transcatheter Aortic Valve Implantation

  2021cites this paper
• Polymorphisms in the GCK gene increase the risk of clopidogrel resistance in stable coronary artery disease (SCAD) patients

  2021cites this paper
• Antiplatelet and antithrombotic therapy in diabetic patients recent updates

  2021cites this paper
• Aspirin for Primary Prevention of Cardiovascular Disease in the 21st Century: A Review of the Evidence.

  2021cites this paper
• Bleeding and Clotting Disorders

  2021cites this paper
• Diabetes-Related Factors and the Effects of Ticagrelor Plus Aspirin in the THEMIS and THEMIS-PCI Trials.

  2021cites this paper
• Efficacy and Safety of Ticagrelor in Diabetes Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials

  2021cites this paper
• Use of the VerifyNow point of care assay to assess the pharmacodynamic effects of loading and maintenance dose regimens of prasugrel and ticagrelor

  2021cites this paper
• Impact Of Chronic Kidney Disease On The Pharmacodynamic And Pharmacokinetic Effects Of Ticagrelor In Patients With Diabetes Mellitus And Coronary Artery Disease.

  2021cites this paper
• Ischemic and bleeding risk by type 2 diabetes clusters in patients with acute coronary syndrome

  2021cites this paper
• The Association between Glycosylated Hemoglobin Level and Platelets Reactivity in Patients with Diabetes Mellitus Undergoing Elective Coronary Artery Bypass Grafting

  2021cites this paper
• The multifaceted contribution of platelets in the emergence and aftermath of acute cardiovascular events.

  2021cites this paper
• High HbA1c is associated with decreased 6-month survival and poor outcomes after out-of-hospital cardiac arrest: a retrospective cohort study

  2020cites this paper
• Parkin Coordinates Platelet Stress Response in Diabetes Mellitus: A Big Role in a Small Cell

  2020cites this paper
• Platelet Aggregation Capacity of Clopidogrel Bisulphate Inhibited by Rabeprazole and Simvastatin in Patients Undergoing Myocardial Infarction in a Tertiary Care System: Drug Interaction Study

  2020cites this paper
• An updated drug profile of ticagrelor with considerations on the treatment of patients with coronary artery disease and diabetes mellitus

  2020cites this paper
• Association between High On-Aspirin Platelet Reactivity and Reduced Superoxide Dismutase Activity in Patients Affected by Type 2 Diabetes Mellitus or Primary Hypercholesterolemia

  2020cites this paper
• PCSK9 Enhances Platelet Activation, Thrombosis, and Myocardial Infarct Expansion by Binding to Platelet CD36.

  2020cites this paper
• Early targeted DNA methylation profiling of CD04+/CD08+ T cells reveals pathogenic mechanisms in different stages of impaired glucose homeostasis Cardiovascular Diabetology

  2020cites this paper
• Human Decidua Basalis mesenchymal stem/stromal cells reverse the damaging effects of high level of glucose on endothelial cells in vitro

  2020cites this paper
• Ticagrelor or Prasugrel in Patients With Acute Coronary Syndromes and Diabetes Mellitus.

  2020cites this paper
• Targeting multiple domains of residual cardiovascular disease risk in patients with diabetes.

  2020cites this paper
• Vascular Complications in Type 2 Diabetes

  2020cites this paper
• SCAI position statement on optimal percutaneous coronary interventional therapy for complex coronary artery disease

  2020cites this paper
• P2Y12 inhibitors during and after acute coronary syndrome, where do we stand in 2020?

  2020cites this paper
• The cardiovascular effects of the treatments for diabetes mellitus : the effect of SIRT-1 activation on markers of endothelial function, arterial stiffness and thrombosis, and the effect of hypoglycaemia on myocardial perfusion and biomarkers of ischaemia

  2020cites this paper
• Ticagrelor monotherapy in patients with diabetes mellitus undergoing percutaneous coronary interventions: insights from the TWILIGHT trial.

  2020cites this paper
• Effect of advanced glycation end products on platelet activation and aggregation: a comparative study of the role of glyoxal and methylglyoxal

  2020cites this paper
• Comparative influence of bleeding and ischemic risk factors on diabetic patients undergoing percutaneous coronary intervention with everolimus‐eluting stents

  2020cites this paper
• Thromboembolic and Bleeding Risk in Atrial Fibrillation Patients with Chronic Kidney Disease: Role of Anticoagulation Therapy

  2020cites this paper
• Genetic polymorphisms of high platelet reactivity in Chinese patients with coronary heart disease under clopidogrel therapy

  2020cites this paper
• Urinary Thromboxane Production in Diabetic and Non-Diabetic Patients of Acute Coronary Syndrome

  2020cites this paper
• Ticagrelor with or without Aspirin in High-Risk Patients with Diabetes Mellitus undergoing Percutaneous Coronary Intervention.

  2020cites this paper
• Pharmacokinetics and Pharmacodynamics of Approved and Investigational P2Y12 Receptor Antagonists

  2020cites this paper
• Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association.

  2020cites this paper
• Antithrombotic Therapy for Atherosclerotic Cardiovascular Disease Risk Mitigation in Patients With Coronary Artery Disease and Diabetes Mellitus

  2020cites this paper
• Association of diabetes with outcomes in patients undergoing contemporary percutaneous coronary intervention: Pre-specified subgroup analysis from the randomized GLOBAL LEADERS study.

  2020cites this paper
• Cutaneous vasculopathy and pulmonary thromboembolism in an unstable diabetic cat.

  2020cites this paper
• Impact of Diabetes Mellitus on Antithrombotic Management Patterns and Long‐Term Clinical Outcomes in Patients With Acute Coronary Syndrome: Insights From the EPICOR Asia Study

  2020cites this paper
• DNA methylation profiling of CD04+/CD08+ T cells reveals pathogenic mechanisms in increasing hyperglycemia: PIRAMIDE pilot study

  2020cites this paper
• Highlights from the 2019 International Aspirin Foundation Scientific Conference, Rome, 28 June 2019: benefits and risks of antithrombotic therapy for cardiovascular disease prevention

  2020cites this paper
• Effect of Dividing Low Dose Aspirin on Platelet Reactivity and the Correlation with Patient-related Factors

  2020cites this paper
• Long-term effect of clopidogrel in patients with and without diabetes: A systematic review and meta-analysis of randomized controlled trials

  2020cites this paper
• Pharmacodynamic and Pharmacokinetic Effects of a Low Maintenance Dose Ticagrelor Regimen Versus Standard Dose Clopidogrel in Diabetes Mellitus Patients Without Previous Major Cardiovascular Events Undergoing Elective Percutaneous Coronary Intervention: The OPTIMUS-6 Study.

  2020cites this paper
• Does percutaneous transluminal coronary angioplasty (PTCA) have comparable long-term outcomes compared to coronary artery bypass grafting (CABG) in diabetic patients?

  2020cites this paper
• Ticagrelor monotherapy in patients with concomitant diabetes mellitus and chronic kidney disease: a post hoc analysis of the GLOBAL LEADERS trial

  2020cites this paper
• Impact of diabetes mellitus on immature platelet fraction and its association with coronary artery disease

  2020cites this paper
• Optimal Strategy for Antiplatelet Therapy After Coronary Drug-Eluting Stent Implantation in High-Risk “TWILIGHT-like” Patients With Diabetes Mellitus

  2020cites this paper
• Prevalence and predictors of high-on treatment platelet reactivity during prasugrel treatment in patients with acute coronary syndrome undergoing stent implantation.

  2019cites this paper
• Association of GCK gene DNA methylation with the risk of clopidogrel resistance in acute coronary syndrome patients

  2019cites this paper